Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone

Patent 4537776 Issued on August 27, 1985. Estimated Expiration Date:

June 21, 2003. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

2990331

3535422

Pharmaceutical composition
Patent #: 3934013
Issued on: 01/20/1976
Inventor: Poulsen

Vehicle composition containing 1-substituted azacycloheptan-2-ones
Patent #: 3989816
Issued on: 11/02/1976
Inventor: Rajadhyaksha

Potentiated medicaments
Patent #: 4006218
Issued on: 02/01/1977
Inventor: Sipos

Skin moisturizing compositions containing 2-pyrrolidinone
Patent #: 4017641
Issued on: 04/12/1977
Inventor: DiGiulio

Steroid ointment
Patent #: 4070462
Issued on: 01/24/1978
Inventor: Ecker

Process for the treatment of acarid skin infections in animals
Patent #: 4075353
Issued on: 02/21/1978
Inventor: Mandy , et al.

Topical composition containing acetyl salicylic acid
Patent #: 4126681
Issued on: 11/21/1978
Inventor: Reller

Method for treatment of acne
Patent #: 4132781
Issued on: 01/02/1979
Inventor: Stoughton

More ...

Inventor

Cooper, Eugene R.

Assignee

The Procter & Gamble Company

Application

No. 06/506273 filed on 06/21/1983

US Classes:

514/424, Chalcogen bonded directly to the five-membered hetero ring by nonionic bonding514/171, With additional active ingredient514/300, Plural hetero atoms in the bicyclo ring system514/549, Z radical contains carbon to carbon unsaturation514/825, ARTHRITIS514/826, ASTHMA514/859Acne

Examiners

Primary: Roberts, Elbert L.

Attorney, Agent or Firm

International Classes

A61K 45/06 (20060101)
A61K 45/00 (20060101)
A61K 47/22 (20060101)
A61K 31/57 (20060101)

Abstract

Topical pharmaceutical compositions comprising a pharmaceutically-active agent and a novel, penetration-enhancing vehicle or carrier are disclosed. The vehicle or carrier comprises a binary combination of N-(2-Hydroxyethyl) pyrrolidone and a "cell-envelope disordering compound". The compositions provide marked transepidermal and percutaneous delivery of the active selected. A method of treating certain pathologies and conditions responsive to the selected active, systemically or locally, is also disclosed.

Other References

Chemical Abstracts, vol. 100 (1984), Par. 174,945k
Stoughton, "Enhanced Percutaneous Penetration with 1-Dodecylazacycloheptan-2-One", Arch. Derm., 118, pp. 474-477, (1982)
Rosuold, J., et al., "Effect of Formulation on In Vitro Release and In Vivo Absorption of Corticosteroids from Ointments", Medd. Novsk Favm Selsk, 44, 21-45, (1982)
Anjo, D. M., et al., "Methods for Predicting Percutaneous Penetration in Man", Percutaneous Absorption of Steroids, pp. 31-51, Academic Press NY, NY, (1980)
CA 92:153,181j
H. Barnes et al., Br. J. Derm., 93, 459, (1975)
P. J. W. Ayres et al., Br. J. Derm., 99, 307, (1978)
Schaaf and Gross, Dermatologica, 106, 357, (1953)
J. Zatz et al., J. Pharm. Sci., 67, 789, (1978)
S. K. Chandrasekaran et al., J. Pharm. Sci., 67, 1370, (1978)
B. Idson, Cosmetics & Toiletries, 95, 59, (1980)
M. M. Rieger, Cosmetics & Toiletries, 94, 32-37, (1979), and 95, 26-38, (1980)
CA 79: 122,308
U.S. patent application Ser. No. 1,974, 1/8/79, Wickett et al
U.S. patent application Ser. No. 383,391, 6/1/82, Cooper
U.S. patent application Ser. No. 506,275, 6/21/83, Cooper
U.S. patent application Ser. No. 506,274, 6/21/83, Cooper et al